Phosphatidylinositol 3-kinases (PI3Ks) are a family of lipid kinases that integrate signals from growth factors, cytokines and other environmental cues, translating them into intracellular signals that regulate multiple signalling pathways. These pathways control many physiological functions and cellular processes, which include cell proliferation, growth, survival, motility and metabolism [1] [2] [3] . Activating alterations in PI3K are found frequently in a variety of cancers (TABLE 1; for a fully referenced version see  Supplementary information S1 (table) ), making this class of enzymes a prime drug target for anti-cancer therapy 2,4 , and tremendous efforts have been devoted to the development of effective PI3K inhibitors. In clinical trials, initial PI3K directed drugs, mostly in the form of non-isoform-selective pan-PI3K inhibitors, have not yielded exciting results. However, recent preclinical studies have shown that different PI3K isoforms have divergent roles in cellular signalling and cancer, suggesting that inhibitors targeting individual isoforms may achieve greater therapeutic efficacy. Isoform-selective inhibitors are now emerging in the clinic and have shown promising success. In this Review, we provide an update on the current understanding of PI3K isoform-specific functions, differences in the modes of PI3K isoform activation and the progress of isoform-selective inhibitors in preclinical and early clinical studies.
Phosphatidylinositol 3-kinases (PI3Ks) are a family of lipid kinases that integrate signals from growth factors, cytokines and other environmental cues, translating them into intracellular signals that regulate multiple signalling pathways. These pathways control many physiological functions and cellular processes, which include cell proliferation, growth, survival, motility and metabolism [1] [2] [3] . Activating alterations in PI3K are found frequently in a variety of cancers (TABLE 1; for a fully referenced version see Supplementary information S1 (table)), making this class of enzymes a prime drug target for anti-cancer therapy 2, 4 , and tremendous efforts have been devoted to the development of effective PI3K inhibitors. In clinical trials, initial PI3K directed drugs, mostly in the form of non-isoform-selective pan-PI3K inhibitors, have not yielded exciting results. However, recent preclinical studies have shown that different PI3K isoforms have divergent roles in cellular signalling and cancer, suggesting that inhibitors targeting individual isoforms may achieve greater therapeutic efficacy. Isoform-selective inhibitors are now emerging in the clinic and have shown promising success. In this Review, we provide an update on the current understanding of PI3K isoform-specific functions, differences in the modes of PI3K isoform activation and the progress of isoform-selective inhibitors in preclinical and early clinical studies.
Multiple PI3K classes and isoforms
PI3Ks phosphorylate the 3ʹ-hydroxyl group of phosphatidylinositides (PtdIns). They are divided into three classes based on their structures and substrate specificities (FIG. 1) . In mammals, class I PI3Ks are further divided into subclasses IA and IB based on their modes of regulation. Class IA PI3Ks are heterodimers that contain a p110 catalytic subunit and a p85 regulatory subunit. The genes PIK3CA, PIK3CB and PIK3CD encode three highly homologous class IA catalytic isoforms: p110α, p110β and p110δ, respectively. These isoforms associate with any of the five regulatory isoforms: p85α (and its splicing variants p55α and p50α, encoded by PIK3R1), p85β (encoded by PIK3R2) and p55γ (encoded by PIK3R3), collectively called p85-type regulatory subunits (reviewed in REFS 1, 5) . Class IB PI3Ks are heterodimers of a p110γ catalytic subunit (encoded by PIK3CG) coupled with the regulatory isoforms p101 (encoded by PIK3R5) or p87 (also known as p84 or p87 PIKAP , encoded by PIK3R6). Whereas p110α and p110β are ubiquitously expressed, p110δ and p110γ expression is generally restricted to leukocytes 6 . In the absence of activating signals, p85 interacts with p110 and inhibits p110 kinase activity. Following receptor tyrosine kinase (RTK) or G protein-coupled receptor (GPCR) activation, class I PI3Ks are recruited to the plasma membrane, where p85 inhibition of p110 is relieved and p110 phosphorylates PtdIns 4,5-bisphosphate (PtdIns(4,5)P 2 ) to generate PtdIns(3,4,5)P 3 (FIG. 2a) . This lipid product acts as a second messenger, activating AKT-dependent and AKT-independent downstream signalling pathways (reviewed in REFS 1-3). The [15] [16] [17] [18] .
Alterations of PI3K isoforms in cancer
Overactivation of the PI3K pathway is one of the most frequent events in human tumours. The most common mechanism leading to aberrant PI3K signalling is somatic loss of PTEN by genetic or epigenetic alterations (reviewed in REFS 19, 20) . The PI3K pathway can also be upregulated by activation of RTKs or alterations in the isoforms of PI3K itself (TABLE 1) .
Class I PI3K catalytic isoform alterations. The transforming potential of class I PI3K catalytic isoforms was first demonstrated by studies in the late 1990s and early 2000s, which showed that fusion of p110α to viral sequences 21 , or the SRC myristoylation sequence [22] [23] [24] , was activating and highly oncogenic. The discovery of frequent PIK3CA mutations in human cancers in 2004 (REF. 25 ) brought PI3K to the forefront as a key driver of cancer and a potential drug target. PIK3CA mutations have since been firmly established as causative in many cancer types (TABLE 1) . Missense mutations occur in all domains of p110α, but most cluster in two 'hot spots' , the most common being E542K and E545K in the helical domain, and H1047R in the kinase domain. Cellbased analyses confirmed that these hotspot mutations confer transformation by the constitutive activation of p110α 23, 26, 27 . Subsequently, several studies using genetically engineered mouse models (GEMMs) demonstrated roles for mutant PIK3CA in tumour initiation, progression and maintenance [28] [29] [30] [31] [32] (see Supplementary  information S2 (table) ). Helical domain mutations Figure 1 | The PI3K family comprises several classes and isoforms. Phosphatidylinositol 3-kinases (PI3Ks) are classified on the basis of their substrate specificities and structures. In vivo, class IA and IB PI3Ks phosphorylate phosphatidylinositide 4,5-bisphosphate (PtdIns(4,5)P 2 ), and class III PI3Ks phosphorylate PtdIns. Some evidence suggests that class II PI3Ks may also preferentially phosphorylate PtdIns in vivo [8] [9] [10] . Class IA PI3Ks are heterodimers of a p110 catalytic subunit and a p85-type regulatory subunit. Class IA catalytic isoforms (p110α, p110β and p110δ) have a p85-binding domain (p85-BD), a RAS-binding domain (RBD), a helical domain and a catalytic domain. Class IA p85 regulatory isoforms (p85α, p85β, p55α, p55γ and p50α) have an inter-SH2 (iSH2) domain that binds to class IA catalytic subunits, flanked by SH2 domains that bind to phosphorylated YXXM motifs. The longer isoforms, p85α and p85β, additionally have amino-terminal SH3 and breakpoint cluster homology (BH) domains. Class IB PI3Ks are heterodimers of a p110γ catalytic subunit and a p101 or p87 regulatory subunit. The p110γ subunit has an RBD, a helical domain and a catalytic domain. The domain structures of p101 and p87 are not fully known, but a carboxy-terminal region of p101 has been shown to bind to G βγ subunits 120 . The monomeric class II isoforms (PI3K-C2α, PI3K-C2β and PI3K-C2γ) have an RBD, a helical domain and a catalytic domain. VPS34 (the only class III PI3K) has helical and catalytic domains. VPS34 forms a constitutive heterodimer with the myristoylated, membraneassociated VPS15 protein. reduce inhibition of p110α by p85 or facilitate direct interaction of p110α with insulin receptor substrate 1 (IRS1) 37 , whereas kinase domain mutations increase interaction of p110α with lipid membranes 33, 36, 38 . Other PIK3CA mutations mimic distinct structural conformation changes that occur during activation of PI3K 36 . Interestingly, some of these mutations in PIK3CA have also been reported in congenital mosaic overgrowth syndromes [39] [40] [41] [42] . By contrast, mutations in other class I catalytic isoforms are rare. Although activating PIK3CD mutations have been described in immune deficiencies 43, 44 , they have not been linked to cancer. One PIK3CB mutation was detected in a single case of breast cancer 45 ; this helical domain substitution enhances basal PI3K activation, potentially by increasing p110β association with membranes 46 . Recent structural studies have suggested that p110β may be less inhibited by p85 and thus has a higher basal transforming potential. Interestingly, p110δ expression has been detected in some human solid cancer cell lines 50 , and overexpression of wild-type p110β, p110δ or p110γ, but not p110α, transforms cells in vitro 51 . This is consistent with the fact that PIK3CB, PIK3CD and PIK3CG are generally amplified or overexpressed, but not mutated, in cancers (TABLE 1) .
Class I PI3K regulatory isoform alterations. Recent studies have converged to implicate the p85 regulatory isoforms in tumorigenesis. Since the initial discovery of PIK3R1 mutations in human cancer cell lines and primary tumours 52 , somatic mutations in PIK3R1 have been identified in several different cancers [53] [54] [55] [56] [57] (TABLE 1) .
Most of these mutations are substitutions or in-frame ). Although class II PI3Ks can phosphorylate both PtdIns and PtdIns(4)P in vitro, this class may preferentially phosphorylate PtdIns (shown as PI) to generate PtdIns(3)P (shown as PIP) in vivo [8] [9] [10] . Class II PI3Ks regulate cellular functions including glucose transport, endocytosis, cell migration and survival. Myotubularin (MTM) family phosphatases remove the 3ʹ phosphate from PtdIns(3)P to inactivate class II PI3K signalling. c | The class III VPS34-VPS15 heterodimer is found in distinct multiprotein complexes, which have specific cellular functions. VPS34 may be activated by stimuli including amino acids, glucose and other nutrients, and it phosphorylates PtdIns (shown as PI) to generate PtdIns(3)P. It has crucial roles in autophagy, endosomal trafficking and phagocytosis. MTM family phosphatases remove the 3ʹ phosphate from PtdIns(3)P to inactivate class III PI3K signalling. Part a adapted from REF. 2 , Nature Publishing Group.
Inter-SRC homology 2 domain
(iSH2 domain). The domain of p85 regulatory phosphatidylinositol 3-kinase (PI3K) isoforms that is located between the carboxy-and amino-terminal SH2 domains and that directly interacts with class IA p110 catalytic isoforms.
Megalencephaly syndromes
A collection of sporadic overgrowth disorders characterized by enlarged brain size and other distinct features.
insertions or deletions in the inter-SRC homology 2 domain (iSH2 domain) of p85α [53] [54] [55] [56] , the region of the protein that makes contact with p110 (REF. 33 ), suggesting that this domain may be a mutation hot spot 53 . A number of these iSH2 domain mutants retain the ability to bind to and stabilize p110 isoforms, but promote enhanced PI3K activity and transformation owing to reduced ability to inhibit p110 58, 59) .
In addition, reduced expression of PIK3R1 has been reported in some cancers 57, 60 (TABLE 1) . PIK3R1 mRNA levels inversely correlated with malignancy grade and incidence of metastasis in both breast and liver cancers 57, 60 . In mice, Pik3r1 ablation increased epithelial neoplasia driven by Pten loss 61 and led to spontaneous development of aggressive liver tumours 60 . This work indicates that p85α can negatively regulate PI3K signalling in cancer, and suggests that p85α has tumour suppressive functions in certain tissues 62 . Alterations in genes encoding other regulatory isoforms have also been detected, albeit at a lower frequency. Increased PIK3R2 expression has been reported in breast and colon cancers 63 (TABLE 1) . Consistent with this, over expression of wild-type p85β increased PI3K pathway activation in cells and tumour formation in mice 63 . Somatic PIK3R2 mutations have been found in endo metrial and colorectal cancers 53, 55 , and causative germline PIK3R2 mutations have been reported in megalencephaly syndromes 41 . All PIK3R2 mutations described to date are substitutions with no apparent hotspot regions and, similar to some p85α mutants, mutations in p85β increase PI3K activation without affecting p110 binding 53 . Together, these studies suggest that PI3K regulatory isoforms may contribute to tumorigenesis by several mechanisms.
Class II PI3K isoform alterations. Although class II PI3Ks are not well understood, PIK3C2A or PIK3C2B expression has been implicated in physiological functions important for tumorigenesis 9, [64] [65] [66] [67] . PIK3C2B amplification has been reported in glioblastoma [68] [69] [70] , and somatic PIK3C2B mutations were detected in non-small-cell lung cancer 71 , but the functional consequence of these mutations is unknown. Perhaps the most convincing evidence in favour of a role for class II PI3Ks in tumori genesis comes from a recent study showing that mice with Pik3c2a ablation had compromised angiogenesis and vascular barrier integrity, as well as a significant reduction in the size and microvessel density of implanted tumours 10 . As embryonic Pik3c2a-or Pik3c2b-knockout (KO) mice are viable 72, 73 , a class II-selective PI3K inhibitor might target tumour angiogenesis with tolerable side effects, although toxicity due to the crucial role of PI3K-C2α in maintaining normal renal homeostasis 73 would need to be considered.
Type II inositol 3,4-bisphosphate 4-phosphatase (INPP4B), the phosphatase responsible for dephosphorylation of PtdIns(3,4)P 2 to PtdIns(3)P 74, 75 , has also been implicated in cancer. In human mammary cell lines, INPP4B knockdown increased AKT activation and transformation 75, 76 . INPP4B loss-of-heterozygosity has been detected in cancers 75, 77 , and reduced INPP4B expression has been correlated with high tumour grade, earlier recurrence and decreased survival 75, 76, 78 . Identification of INPP4B as a tumour suppressor suggests that deregulation of the class II PI3K lipid products may contribute towards tumorigenesis.
Class III PI3K isoform alterations.
There is currently little evidence indicating an oncogenic role for VPS34. One recent study suggested that VPS34 is tyrosinephosphorylated and activated downstream of SRC, and its lipid kinase activity is required for SRC-mediated transformation 79 . However, overexpression of wild-type or myristoylated VPS34 was not sufficient to induce cellular transformation 80 . Another study indicated that VPS34 activity might be decreased in the context of activated epidermal growth factor receptor (EGFR) 81 . Further investigations are needed to determine whether VPS34 has a role in transformation.
Divergent roles of class I PI3K catalytic isoforms
Class I PI3K catalytic isoforms share a conserved domain structure. They also use the same lipid substrates and generate the same lipid products. However, despite their similarities, accumulating evidence suggests that these isoforms have distinct roles in mediating PI3K signalling in physiological and oncogenic contexts.
GEMMs have been used to elucidate the roles of individual class I PI3K isoforms. Mice with germline KO of Pik3ca or knock-in (KI) of a kinase-dead Pik3ca allele die at day E10.5 (REFS 82, 83) . Interestingly, Pik3cb-KO mice die much earlier, at day E3.5 (REF. 82 ), while kinase-dead Pik3cb KI mice develop to maturity with minor defects in size and glucose metabolism, and major defects in male fertility 84, 85 . These differences suggest an important kinase-independent scaffolding role for p110β 84 . Germline inactivation of Pik3cd or Pik3cg by KO or KI of kinase-dead alleles yields viable mice that grow to adulthood; however, loss of p110δ results in functional defects in lymphocytes, neutrophils and mast cells [86] [87] [88] [89] , while loss of p110γ impairs thymocyte development, T cell activation and neutrophil migration [90] [91] [92] . These studies suggest non-redundant roles in mouse embryonic development for p110α and p110β, the two ubiquitously expressed class I PI3K isoforms, and distinct roles in the immune system and inflammatory response for p110δ and p110γ, the two leukocyte-restricted isoforms.
Technological developments have facilitated further insights into the individual roles of PI3K enzymes. The generation of conditional KO animals using the Cre-loxP recombination system has allowed the functions of each isoform to be studied in different tissues, at different stages of development and in different pathological settings (see Supplementary information S2 (table)). Additional progress has come from studies using RNA interference (RNAi) and a new generation of isoformselective PI3K inhibitors. These have advanced our understanding of the roles of class I catalytic isoforms in mediating signalling downstream of RTKs, GPCRs and small GTPases (FIG. 3) and in the context of PTEN deficiency (FIG. 4a) . Nature Reviews | Cancer Mediating RTK signalling. Binding of growth factor ligands induces RTK dimerization, activation and auto-phosphorylation of tyrosine-containing YXXM motifs on the receptors or their associated adaptor proteins. Class IA p110-p85 heterodimers are then recruited to activated RTKs through the direct interactions of p85 SH2 domains with these phosphorylated YXXM motifs [93] [94] [95] (FIG. 2a) . Accordingly, p110α, p110β
and p110δ can form complexes with activated RTKs (FIG. 3a) and might be expected to mediate growth factor signalling. Studies using isoform-selective pharmacological inhibitors and genetic inactivation or ablation indicated that loss of p110α activity was sufficient to block PI3K signalling to a large extent in response to a number of growth factors [96] [97] [98] [99] [100] [101] . Notably, genetic ablation or Figure 3 | Divergent roles of class I PI3K catalytic isoforms in different signalling contexts. a | Class I phosphatidylinositol 3-kinases (PI3Ks) mediate signalling downstream of receptor tyrosine kinases (RTKs), G-protein coupled receptors (GPCRs) and small GTPases. Left: p85 regulatory subunits bind to phosphorylated YXXM motifs on activated RTKs. As p110α, p110β and p110δ bind to p85, these isoforms mediate signalling downstream of RTKs. Recent evidence also suggests that p87-p110γ may be activated by certain RTKs 110 . Middle: small GTPases synergize with RTK and GPCR signals to directly activate PI3Ks by interacting with their RAS-binding domains (RBDs). Isoforms p110α, p110δ and p110γ bind to RAS family GTPases, while p110β binds to the RHO family GTPases RAC1 and CDC42 (REF. 143 ). Right: G α and G βγ proteins dissociate from activated GPCRs. Catalytic isoforms p110β and p110γ, and regulatory isoform p101, directly bind to and are activated by G βγ . The p110δ isoform may be activated downstream of GPCRs, but the mechanism is unknown [126] [127] [128] . G α proteins have been reported to directly bind to and inhibit p110α [129] [130] [131] . b | Competition model for p110α and p110β regulation of RTK signalling 96 is shown. Both p85-p110α and p85-p110β compete for phosphorylated YXXM sites on activated RTKs. However, the maximal specific activity and enzymatic rate of p110α are higher than those of p110β 108, 109 , and RTK-associated p110α may have higher lipid kinase activity than p110β 96 . In this model, loss or inactivation of p110α or p110β differentially modulates RTK signalling. Knockout (KO) of p110α allows all sites to be occupied by the less active p110β subunit, decreasing RTK output. Conversely, KO of p110β allows all sites to be bound by the more active p110α subunit, increasing RTK output. Genetically or pharmacologically inactivated p110α or p110β can still bind to RTKs but cannot signal, reducing RTK output. Part a adapted from REF. 3 , Nature Publishing Group. 
Upregulation or mutation of:
PtdIns(4,5)P 2 PtdIns(4,5)P 2 PtdIns(3,4,5)P 3 PTEN Basal activity (table) ). CDK4, cyclin-dependent kinase 4; EGFR, epithelial growth factor receptor; ER, oestrogen receptor; FGFR, fibroblast growth factor receptor; HSP90, heat shock protein 90; IGF1R, insulin-like growth factor 1 receptor; NF-κB, nuclear factor κB; PARP, poly-(ADP-ribose) polymerase; SYK, spleen tyrosine kinase; VEGFR, vascular endothelial growth factor receptor.
RAS superfamily proteins
Small monomeric membraneassociated GTPases, which are divided into the RAS, RHO, RAB, ARF and RAN subfamilies based on structure and function.
RAS GTPases
A subfamily of RAS superfamily GTPases that have crucial roles in signal transduction. In mammals, the three major RAS subfamily members are HRAS, KRAS and NRAS.
inactivation of p110β had only a modest effect on PI3K signalling following acute RTK activation 84, 102, 103 . It was suggested that the relative abundance of catalytic isoforms in a particular tissue might dictate which isoforms are dominant in mediating RTK signalling 104 . This may explain the role of p110δ, which is mainly expressed in leukocytes and is the primary isoform regulating PI3K signalling downstream of certain RTKs in mast cells and macrophages 87, 105, 106 . However, differential expression does not completely explain isoform dependence, as in many tissues p110β levels are comparable to, or even higher than, levels of p110α 107 . The involvement of p110β in RTK signalling remained puzzling until a recent study from our group suggested a new model. In mice, whereas p110α ablation blocked normal mammary development and mammary tumorigenesis driven by polyoma middle T (PyMT) or HER2 (also known as ERBB2), p110β ablation increased mammary gland outgrowth and accelerated tumour formation driven by these oncogenic RTKs 96 . To explain this negative role of p110β in mammary tumour formation, a competition model was proposed: if p110α has higher RTK-associated lipid kinase activity than p110β, then the less-active p110β could compete with p110α for phosphorylated YXXM sites on receptors to modulate PI3K signal strength downstream of RTKs 96 (FIG. 3b) .
Although direct comparison of RTK-associated p110α and p110β lipid kinase activity has not been shown, the maximal specific activity and enzymatic rate of p110α are higher than that of p110β 108, 109 . Biochemical data were consistent with this proposed model, showing that in p110β-KO cells, activated RTKs had more bound p110α and higher associated lipid kinase activity 96 . Furthermore, pharmacologically inactivated p110β could still compete with p110α for binding sites on activated receptors, slightly reducing signalling and tumour growth driven by PyMT or HER2 (REF. 96 ). This model also explains the moderately decreased AKT activation, mild hyper glycaemia and delayed HER2-driven tumour formation observed in mice with KI of kinasedead p110β 84 , a scenario mimicking p110β-selective kinase inhibition. These studies not only reveal a new p110β-based regulatory mechanism in RTK-mediated PI3K signalling but also identify p110α as an important target in cancers driven by oncogenic RTKs.
Initial studies suggested that class IA isoforms mediated signalling downstream of RTKs, while the class IB isoform signalled downstream of GPCRs. Although p110γ activation by GPCRs is well established, a recent report suggested that this class IB isoform might also function downstream of RTKs through the regulatory isoform p87 in mouse myeloid cells 110 (FIG. 3a) . Given that p87 and p101 may have specific tissue distribution [111] [112] [113] and non-redundant functions 110, 111, 113, 114 , this suggests that the two class IB regulatory isoforms may mediate p110γ activation in response to specific upstream signals.
Mediating GPCR signalling.
GPCRs are a family of receptors that contain seven-transmembrane domains and associate with heterotrimeric G proteins composed of the G α and G βγ subunits. Ligand binding to GPCRs results in allosteric activation and dissociation of bound G proteins into their separate subunits, which can then act on intracellular targets.
The only class IB catalytic PI3K isoform, p110γ, is activated by G proteins [115] [116] [117] (FIG. 2a) . Although association of p110γ with either its p101 regulatory isoform or its p87 regulatory isoform increased its activation in response to G βγ 115, 118, 119 , recent evidence suggests that p101 is the main regulatory isoform involved in GPCRmediated p110γ signalling 110, 114 (FIG. 3a) . Both p110γ and p101 interact directly with G βγ hetero dimers, and these contacts are crucial for signalling and transformation mediated by p110γ 115, 120 . Recent studies have shown that in myeloid cells, p110γ can be activated by GPCR and RTK signals in a RAS-or RAP1A-dependent manner to mediate integrin α4β1 activity, leading to tumour inflammation and progression 110, 121 . Thus, p110γ-mediated signalling may contribute to tumorigenesis by controlling both tumour cell characteristics and the tumour microenvironment.
Interestingly, in vitro experiments 117,122-124 and subsequent GEMM studies 84, 102, 103 suggest a role for p110β in G protein-mediated PI3K signalling (FIG. 2a) . Recently, a region in the C2-helical domain linker of p110β was shown to bind to G βγ subunits (FIG. 3a) ; this region is not present in other class IA isoforms 125 and is similar to the region of p110γ that binds to G βγ 120 . Abrogation of p110β-G βγ interaction blocked p110β-mediated signalling and transformation downstream of GPCRs, and inhibited the proliferation and invasiveness of cancer cells 125 . Although p110δ does not directly interact with G proteins, a non-redundant role for this isoform in GPCR-mediated leukocyte migration has been shown in certain contexts [126] [127] [128] ; however, the mechanism of p110δ activation downstream of GPCRs is unknown. It has also been reported that some G α proteins directly bind to and inhibit p110α [129] [130] [131] . Clearly, class I PI3K isoforms cooperate with GPCRs in several different ways to regulate signalling and transformation.
Downstream of RAS and other small GTPases.
RAS superfamily proteins are direct activators of the PI3K pathway. All class I PI3K catalytic isoforms have an aminoterminal RAS-binding domain (RBD) (FIG. 1) , allowing them to interact with RAS GTPases or other RAS superfamily members (FIG. 3a) . Activated or oncogenic mutant RAS proteins directly bind to, and increase the enzymatic activity of, both p110α 132, 133 and p110γ [134] [135] [136] . Cellular and structural studies suggest that p110γ association with RAS might both increase its membrane translocation 114, 135 and allosterically increase p110γ kinase activity 135 . Interestingly, RAS is required for the activation of p110γ bound to the regulatory isoform p87, but not to p101 (REF. 114 ). In vitro, the transforming capability of both helical domain p110α mutants 34, 137 and overexpressed wild-type p110γ 51, 138 are dependent on their association with RAS. GEMM studies using KI of Pik3ca with an RBD mutation or KO of endogenous Pik3ca showed that the p110α-RAS interaction is crucial for both the initiation and maintenance of lung tumours 139, 140 and the development of myeloid leukaemia 141 driven
RHO family GTPases
A subfamily of RAS superfamily proteins that share similar roles in signal transduction to RAS GTPases and are best characterized for their roles in the regulation of cell shape, movement and polarity.
by oncogenic KRAS. In mice, p110γ-RAS binding is required for inflammation-induced PtdIns(3,4,5)P 3 accumulation 142 and inflammation-associated tumour progression 110, 121 . These studies highlight the importance of p110α or p110γ interactions with RAS in both normal PI3K signalling and transformation.
Although p110δ was shown to bind to RAS in vitro 143, 144 , some studies indicated that p110δ kinase activity was not stimulated by HRAS, NRAS or KRAS, but instead by RRAS and TC21 (also known as RRAS2) 145, 146 . Furthermore, B and T cells derived from Tc21-KO mice had diminished PI3K activity and recruitment of p110δ to T cell receptors (TCRs) and B cell receptors (BCRs), suggesting that TC21 might function upstream of p110δ 147 . Thus, PI3K signalling through p110δ may be regulated by additional RAS subfamily members.
It was initially anticipated that all p110 isoforms with a RBD might interact with RAS GTPases. Surprisingly, in vitro studies suggested that the kinase activity of p110β was not stimulated by any RAS subfamily members 146 . A recent extensive biochemical study showed that p110β is instead regulated by RAC1 and CDC42 RHO family GTPases 143 (FIG. 3a) . Direct interactions between the p110β RBD and RAC1 are important for GPCR-mediated activation of p110β 143 , indicating cooperative G βγ and RHO GTPase signalling through p110β. Previous studies reported that an intact RBD was required for signalling and oncogenic transformation by wild-type p110β in cultured cells 51, 138 , suggesting a potential role for RHO GTPase interaction with p110β in transformation. Notably, RAC1 and CDC42 can also be activated downstream of PI3K by PtdIns(3,4,5)P 3 -dependent guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs) [148] [149] [150] . The finding of distinct p110β regulation by RAC1 and CDC42 expands PI3K signalling input by GTPases beyond the RAS subfamily, and also supports the notion that PI3K can act both upstream and downstream of GTPases, potentially allowing positive feedback loops in cancer settings.
PTEN deficiency.
The PTEN lipid phosphatase counteracts class I PI3K activity, making it an important tumour suppressor. Somatic loss of PTEN in human cancers is common. Germline PTEN mutations are also found in several genetic disorders characterized by multiple hamartomas with overgrowth phenotypes, collectively termed PTEN hamartoma tumour syndromes (PHTS) 151 . Pten-KO mouse models provided a tool to explore the molecular mechanisms underlying diseases caused by PTEN loss. While embryonic Pten KO is lethal 152, 153 , heterozygous or conditional Pten KO animals recapitulated human disease phenotypes, including development of prostate cancer [154] [155] [156] . Surprisingly, ablation of p110β, but not of p110α, blocked prostatic intra epithelial neoplasia induced by PTEN loss 102 . Subsequent studies showed a correlation between PTEN deficiency and sensitivity to p110β knockdown or inhibition in human cancer cell lines, both in vitro and in mouse xenografts [157] [158] [159] . However, the mechanism governing the specific importance of p110β in the context of PTEN loss remains unknown. Perhaps the unique role for p110β as a convergence point for GPCR and RAC1 or CDC42 signals (FIG. 4a) contributes to the transformation induced by PTEN deficiency. Structural studies have also suggested that compared with p110α, p110β is less inhibited by p85 and may supply a basal level of PtdIns(3,4,5)P 3 (REFS [47] [48] [49] . This may explain why wild-type p110β can be oncogenic when it is overexpressed 51, 138 or when PTEN is lost.
Although p110β is the primary PI3K isoform involved in many cases of tumorigenesis that are driven by PTEN loss, studies have shown that depending on the tissue type and pathology, both p110α and p110β may be involved [160] [161] [162] . Mice with Pten ablation in the basal epidermal compartment require both p110α and p110β for the development of hyperproliferative epidermal lesions closely resembling PHTS 163, 164 . In this model, spatially distinct roles for these isoforms in epidermal compartments were identified: p110α is responsible for RTK signalling in and the survival of suprabasal cells, whereas p110β is important for GPCR signalling in and proliferation of basal cells 164 . In mice with a thymocytespecific Pten KO, not surprisingly both p110δ and p110γ were required for the development of T cell acute lympho blastic leukaemia (T-ALL) 165 . This suggests that in certain contexts, transformations driven by the loss of PTEN may be governed by the PI3K isoforms that are dominant in that tissue or compartment.
As PTEN loss removes one mechanism of PI3K pathway negative regulation, the specific roles of p110 isoforms in this pathogenic context can be influenced by other activating inputs. These can be cues from the tissue microenvironment or other coexisting genetic events. A recent GEMM study showed that concomitant activation of oncogenic KRAS in ovarian endometrioid adenocarcinoma driven by Pten ablation shifted the PI3K isoform reliance from p110β to p110α 162 (FIG. 4a) .
Consistent with this, a subset of PTEN-mutant human endometrioid endometrial cancer cell lines harbouring other PI3K-activating mutations were resistant to p110β inhibition 166 . It is also possible that other genetic events downstream of PI3K, or in PI3K-independent pathways, may render PTEN-null tumours less reliant on PI3K. Thus, determination of isoform dependency in PTEN-deficient tumours remains a challenge.
Therapeutic targeting of PI3K isoforms in cancer
The central role of PI3K in cancer makes it an attractive therapeutic target. Enormous efforts have focused on the development of drugs targeting PI3K, many of which are undergoing clinical evaluation (TABLES 2-4). Unlike drugs targeting other oncogenic kinases (such as those targeting EGFR, BRAF and ALK), PI3K inhibitors have shown limited efficacy as monotherapies in early trials on patients with tumours harbouring PI3K pathway activation 167 . The effectiveness of these early PI3K inhibitors may have been limited by their lack of specificity, by compensatory signalling feedback loops and by coexisting genetic and epigenetic alterations. The development of novel isoform-selective PI3K inhibitors (FIG. 4a) and their rational combination with other therapeutics (FIG. 4b; see Supplementary information S3 (table)) may substantially improve therapeutic outcomes.
Emerging isoform-selective PI3K inhibitors Most PI3K inhibitors in early clinical trials are ATPcompetitive agents that target all class I isoforms with similar potencies. These include pan-PI3K inhibitors (TABLE 2) , such as GDC0941 168 , and dual pan-PI3K and mTOR inhibitors (TABLE 3) , such as BEZ235 (REF. 169 ). Although these drugs display potent preclinical antitumour activity, their successes in clinical trials as single agents have been modest 167 . The therapeutic windows and efficacies of pan-PI3K inhibitors are limited in some cases by adverse drug events arising from a broader spectrum of off-target effects 170 , as well as on-target effects from inhibiting all class I PI3K isoforms regardless of their contribution to tumorigenesis. Isoform-selective inhibitors are emerging in the clinic and may achieve greater efficacy with fewer toxic effects (TABLE 4) .
The most effective single-agent PI3K-based therapy to date is idelalisib (also known as Zydelig (Gilead Sciences), CAL101 or GS1101), a p110δ-selective inhibitor. Idelalisib has achieved notable success in clinical trials for patients with relapsed chronic lymphocytic leukaemia or indolent lymphoma 171, 172 , and has recently been approved by the US Food and Drug Administration for treatment of patients with these cancers. Interestingly, this dramatic response is not due to genetic activation of the PI3K pathway, as neither PI3K mutation nor PTEN loss is common in these malignancies. Given the important role of p110δ in signalling downstream of BCRs 86, 88, 89 and the fact that leukaemic B cells are dependent on BCR signalling, it is likely that idelalisib functions by blocking essential BCR signals. Two recent articles provide great insights into the success of idelalisib trials 173, 174 . In addition to the role of p110δ in B cell malignancies, a recent preclinical study showed that this isoform also contributes to PTEN-null T-ALL 165 . However, p110δ-selective inhibition in this study was insufficient to suppress tumorigenesis; combined inhibition of both p110δ and p110γ was required for effective anti-PI3K therapy 165 . The involvement of p110δ and p110γ in leukocyte signalling and haematological malignancies has drawn great attention, and new inhibitors that simultaneously target both of the isoforms are in clinical trials for B and T cell lymphomas (TABLE 4) . These isoforms may also mediate immune responses that support the growth of solid tumours; in a mouse model, p110γ inhibition blocked myeloid cell recruitment to tumours, thus suppressing malignancy by targeting the tumour microenvironment 110 . Another study indicated that p110δ inhibition impaired tumour growth by disrupting regulatory T cell-mediated immune tolerance 175 . These findings suggest potential new applications for p110δ-or p110γ-selective therapies against cancer.
The frequency of PIK3CA mutations in solid tumours has generated great interest in the potential of p110α-selective inhibitors to target these cancers. Data presented at the 2013 San Antonio Breast Cancer Symposium (SABCS) indicated promising early clinical activity of p110α-selective inhibitors BYL719 or GDC0032 as single agents in patients with PIK3CA-mutant advanced breast tumours 176 . Recent preclinical findings, which show that HER2-or KRASdriven tumours rely on p110α (REFS 96, (139) (140) (141) 162) , highlight the need for clinical evaluation of p110α-selective drugs in these disease settings. In these studies, growth of HER2-or KRAS-driven solid tumours is inhibited at similar levels by pan-and p110α-selective inhibitors 96, 140 , but only modestly by p110β-selective inhibitors 96, 162 . However, further studies are needed to determine the contexts in which simultaneous inhibition of p110α and p110β can improve outcomes of KRAS-or HER2-driven disease.
One drawback of p110α-selective inhibitors is their inevitable on-target adverse effects on insulin signalling and glucose metabolism, as p110α is the main isoform mediating these functions 98, 100 . In the clinic, the effect of p110α-selective inhibitors on glucose homeo stasis must be carefully managed 177 , and is in some cases limiting 167 .
To circumvent this, inhibitors are being developed that specifically target p110α that harbours hotspot mutations. Such agents might be used at high doses with low toxicity, similar to mutant-selective BRAF inhibitors that have had great clinical success 178, 179 . A major obstacle to this approach is the heterogeneity of oncogenic PIK3CA mutations. Some progress has been made with the discovery of GDC0032, which was reported at the 2013 SABCS to have enhanced potency in PIK3CA-mutant breast cancer models 180 ; one preclinical study also 29 . Such drugs would also be ideal for treating congenital overgrowth syndromes caused by PIK3CA mutations occurring during early embryonic development [39] [40] [41] [42] . In these contexts, p110α mutant-selective inhibitors may yield an improved therapeutic index.
Several preclinical studies have documented that certain PTEN-deficient tumours depend on p110β 102, 157, 159 , which prompted a new clinical trial with the p110β-selective inhibitor GSK2636771 in patients with PTEN-deficient advanced solid tumours (trial number NCT01458067). However, as PTEN is a negative regulator of PI3K, isoform-dependency of PTEN-deficient tumours can be complicated because it can be influenced by tissue type, coexisting genetic events and microenvironmental cues that fuel cancer cells. In model systems in which PTEN-deficient tumours are dependent on p110β, addition of oncogenic RTKs, RAS or mutant PIK3CA can shift dependency partially, or totally, to p110α (FIG. 4a) . Recent studies also show that prolonged treatment of PTEN-deficient tumour cells with p110β-selective inhibitors can shift isoform dependency from p110β to p110α (N. Rosen, personal communication). Therefore, in most PTEN-deficient solid tumours, both p110α and p110β should be targeted.
Although development of dual p110α-and p110β-selective inhibitors has been difficult 98 , combinations of individual p110α-and p110β-selective inhibitors might offer flexibility in the dosing of each isoform-selective inhibitor to further reduce toxicity and to increase the therapeutic window. One approach could involve continuous inhibition of p110β to suppress elevated basal PI3K activity due to PTEN loss, combined with pulsatile inhibition of p110α to avoid toxicity due to glucose elevation. Such a strategy might also avoid the reported shift in isoform dependency of tumoursfrom p110α to p110β -after prolonged treatment with the p110α-selective inhibitor BYL719 (J. A. Engelman, personal communication). Ultimately, the success of targeting PI3K in cancer will probably require a better understanding of which PI3K isoforms to target in a given disease setting, improved inhibitors and more careful dosing strategies.
Resistance and combination therapies PI3K-based therapeutic approaches have encountered a number of barriers in the form of intrinsic and acquired resistance mechanisms. Many studies have identified several signalling feedback loops, compensatory parallel signalling pathways and modes of downstream pathway activation that may result in clinical resistance to PI3K inhibitors. Consequently, combination therapies are being developed and evaluated in both preclinical and clinical settings (FIG. 4b; see Supplementary information S3 (table)), and will be necessary to maximize clinical efficacy of PI3K inhibitors.
The first indication of feedback loops in the PI3K pathway came from experiments with mTOR inhibitors. In early studies, mTOR inhibition led to p70 ribosomal protein S6 kinase (S6K) suppression, IRS1 upregulation and PI3K-AKT activation 181 . This prompted the development of dual pan-PI3K and mTOR inhibitors, which are currently in clinical trials (TABLE 3) . Interestingly, feedback loops can also arise from dual PI3K and mTOR inhibition. A recent preclinical report suggested that blocking PI3K and mTOR activated the Janus kinase 2 (JAK2)-signal transducer and activator of transcription 5 (STAT5) signalling axis by IRS1, generating resistance to PI3K and mTOR inhibition, which could be overcome by targeting JAK2 (REF. 182) . Similarly, in another preclinical study, treatment with BEZ235 increased phosphory lation of multiple signalling molecules, including STAT3, STAT5, JUN and the p90 ribosomal S6 kinase (p90RSK) 183 . Isoform-selective PI3K inhibitors can also generate feedback loops: in a recent study of PIK3CA-mutant breast tumours, mTOR complex 1 (mTORC1) reactivation by insulin-like growth factor 1 (IGF1) and neuregulin 1 (NRG1) was associated with tumour resistance to the p110α-selective agent BYL719, necessitating concurrent mTORC1 inhibition using RAD001 (REF. 184 ). Inhibiting both PI3K and mTOR, possibly in conjunction with additional signalling pathways, may be required to achieve effective antitumour activity.
Another important resistance mechanism to PI3K pathway inhibition is the increased expression of RTKs, such as HER3, IGF1 receptor (IGF1R), insulin receptor (IR) and EGFR, by forkhead box O (FOXO)-mediated transcriptional upregulation 185 . Robust HER3 induction in response to PI3K inhibition has been reported in several tumour types 183, 186, 187 . Although HER3 itself does not have tyrosine kinase activity, it dimerizes with EGFR, HER2 or HER4, which hyperactivates the PI3K pathway and dampens the efficacy of PI3K drugs. A preclinical study showed that the combination of the HER3-neutralizing antibody LJM716 and the p110α-selective inhibitor BYL719 potently blocked PI3K signalling and growth of HER2-positive breast tumour xenografts, even without a direct HER2 antagonist 188 . Similarly, the combination of the dual EGFR and HER3 inhibitor MEHD7945A with a PI3K inhibitor (GDC0941) or AKT inhibitor (GDC0068) effectively blocked the growth of triple-negative breast cancer cells in vitro and in xenografts in a preclinical study 189 . Blocking PI3K, along with upstream RTKs, may therefore circumvent certain PI3K therapy resistance mechanisms (FIG. 4b) .
Activation of convergent signalling pathways, for example, the RAS-RAF-MEK-ERK pathway, can also lead to PI3K pathway inhibition resistance. Mutated RAS can activate both RAF-ERK and PI3K-AKT-mTOR pathways in cancer cells; blocking the PI3K pathway in such cells leads to upregulation of the ERK pathway 190 . Inhibition of both PI3K and ERK pathways successfully suppressed the growth of cancer cells in mouse models 28, 140, 191 , and combinations of MEK inhibitors and panor isoform-selective PI3K agents are being evaluated in clinical trials. However, there is preclinical evidence that some of these combinations may be limited owing to synergistic toxicity 140 . Preclinical studies suggest that pulsatile inhibition of both PI3K and ERK pathways may provide more effective antitumour activity while limiting toxic effects 191 , suggesting that optimization of such combinations in the clinic will require careful dosing strategies.
Another method of resistance to PI3K-directed therapies arises from the activation of transcription downstream, or outside, of the PI3K pathway. Several reports have indicated that amplification or overexpression of MYC 29, 192 or activation of the NOTCH and WNT-β-catenin pathways 193, 194 are mechanisms of resistance to PI3K inhibition. Recently, the bromodomain and extraterminal (BET) inhibitor JQ1 has been shown to downregulate transcription of MYC, among other targets 195 . XAV939 has also been shown to be an inhibitor of WNT-β-catenin-mediated transcription 196 . Combining PI3K inhibition with treatment by these agents is being actively pursued in preclinical settings.
Other combination therapies have been suggested by assessing pathways that may synergize with PI3K (FIG. 4b) . As presented at the 2012 and 2013 SABCS, anti-oestrogen therapies are being tested in combination with PI3K inhibitors in clinical trials for patients with breast cancer 176, 197, 198 . In a brain tumour study, coordinated activation of sonic hedgehog (SHH) and PI3K signalling was found in PTEN-deficient glioblastoma; a combination of BKM120 (a pan-PI3K inhibitor) and LED225 (a smoothened (SMO) inhibitor that blocks SHH signalling) resulted in synergistic antitumour effects 199 . Poly-(ADP-ribose) polymerase (PARP) and PI3K inhibitors cooperate in prostate and triple-negative breast cancers [200] [201] [202] . It seems that PI3K inhibition downregulates BRCA1 and BRCA2, impairing homologous recombination and sensitizing BRCAwild-type cancer cells to PARP inhibition. Another attractive approach is the combination of PI3K-targeted agents with drugs that suppress anti-apoptotic factors. B cell lymphoma 2 (BCL2), myeloid cell leukaemia sequence 1 (MCL1) and other pro-survival proteins are frequently upregulated in cancer, and may explain why PI3K inhibition is often cytostatic in tumour cells. BCL2 or MCL1 suppression may induce cytotoxicity in response to PI3K inhibition 203 . Finally, an emerging approach is to combine PI3K inhibitors with agents that disrupt the cell cycle machinery 204 . The INK4A-cyclin D-cyclin-dependent kinase 4 (CDK4)-CDK6 pathway is frequently dysregulated in cancer. A number of CDK4 and CDK6 inhibitors, including LEE011 and palbociclib (also known as PD0332991), are entering clinical trials in combination with pan-or p110α-selective inhibitors. Such rational combination therapies will be required to increase the success of PI3K inhibitors.
Conclusions and perspective
Targeting the PI3K pathway remains both an opportunity and a challenge for anti-cancer therapy. Recent advances have provided the framework and rationale for inhibiting specific class I PI3K catalytic isoforms. We have learned a great deal about the divergent roles of these isoforms in different signalling contexts, and we are beginning to understand the importance of each isoform in various tissues, compartments and cancer types. These findings have informed preclinical and clinical studies with isoform-selective PI3K agents, which offer improved specificity and reduced toxicity over first-generation pan-PI3K drugs. Isoformselective PI3K inhibitors have seen promising success in early-and late-stage clinical trials for solid and haematological malignancies, highlighting the potential for isoform-selective PI3K therapeutics.
Although substantial progress has been made, further efforts are needed. We have only recently begun to appreciate the importance of class I regulatory isoforms in tumorigenesis. The different ways in which p85 subunits contribute to cancer, and the effective means to pharmacologically inhibit these mechanisms, are still not fully understood. Similarly, while a recent study suggested that the class II isoform PI3K-C2α is important for pathophysiological angiogenesis, the roles of class II and III PI3Ks in cancer remain unclear.
For the class I catalytic isoforms, we must continue to precisely define the disease settings in which different PI3K isoforms need to be targeted. To better advise isoform-selective therapeutic strategies, a set of biomarkers to predict the active p110 isoforms in a given tumour would be ideal, but development of this requires systematic studies. Continued work to understand the underlying cellular programmes that protect tumours with aberrant PI3K activation from PI3K-targeted therapy is also important. This allows better rational design of combination therapies, which will be necessary to overcome compensatory pathway activation and acquired resistance mechanisms, and to maximize the antitumour activity of PI3K inhibitors. Dosing strategies also need to be carefully considered, as recent studies suggest that in some cases pulsatile inhibition may reduce toxicity without sacrificing efficacy. Progress in these areas should increase the effectiveness of PI3K-directed therapies in the clinic.
